Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H39N3O4.H2O4S |
Molecular Weight | 555.684 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.NC(=O)C1=CC=CC(=C1)[C@@H]2C[C@@H]3CC[C@H](C2)N3CCN(CC4CCCCC4)C(=O)[C@@H](O)CO
InChI
InChIKey=QNFFAKFVKCGLPK-WTKDUOFSSA-N
InChI=1S/C26H39N3O4.H2O4S/c27-25(32)20-8-4-7-19(13-20)21-14-22-9-10-23(15-21)29(22)12-11-28(26(33)24(31)17-30)16-18-5-2-1-3-6-18;1-5(2,3)4/h4,7-8,13,18,21-24,30-31H,1-3,5-6,9-12,14-17H2,(H2,27,32);(H2,1,2,3,4)/t21-,22+,23-,24-;/m0./s1
Axelopran (previously known as TD-1211), a peripherally selective, multivalent µ-opioid receptor antagonist that is under development by Theravance Biopharma. This drug participated in phase II clinical trials in subjects with opioid-induced constipation. The most common adverse events were abdominal pain, nausea, and diarrhea. There were no indications of opioid withdrawal effects or reductions in opioid analgesia in patients treated with axelopran.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01401985
Capsules once daily
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C681
Created by
admin on Sat Dec 16 08:37:29 GMT 2023 , Edited by admin on Sat Dec 16 08:37:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL3137313
Created by
admin on Sat Dec 16 08:37:29 GMT 2023 , Edited by admin on Sat Dec 16 08:37:29 GMT 2023
|
PRIMARY | |||
|
300000044464
Created by
admin on Sat Dec 16 08:37:29 GMT 2023 , Edited by admin on Sat Dec 16 08:37:29 GMT 2023
|
PRIMARY | |||
|
DBSALT002121
Created by
admin on Sat Dec 16 08:37:29 GMT 2023 , Edited by admin on Sat Dec 16 08:37:29 GMT 2023
|
PRIMARY | |||
|
BC-62
Created by
admin on Sat Dec 16 08:37:29 GMT 2023 , Edited by admin on Sat Dec 16 08:37:29 GMT 2023
|
PRIMARY | |||
|
949904-50-1
Created by
admin on Sat Dec 16 08:37:29 GMT 2023 , Edited by admin on Sat Dec 16 08:37:29 GMT 2023
|
PRIMARY | |||
|
1050202-71-5
Created by
admin on Sat Dec 16 08:37:29 GMT 2023 , Edited by admin on Sat Dec 16 08:37:29 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
C142943
Created by
admin on Sat Dec 16 08:37:29 GMT 2023 , Edited by admin on Sat Dec 16 08:37:29 GMT 2023
|
PRIMARY | |||
|
8OJM0A31U9
Created by
admin on Sat Dec 16 08:37:29 GMT 2023 , Edited by admin on Sat Dec 16 08:37:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD